Literature DB >> 20573481

Expectations, validity, and reality in omics.

John P A Ioannidis1.   

Abstract

Diverse methods of large-scale measurements of biological processes have emerged in the last 15 years and their list is growing rapidly. Almost invariably, these advances in omics have been associated with major expectations of transforming not only biological knowledge but also medicine and health. However, practical applications of omics in biomedicine have often suffered from poor attention to issues of validity. As a consequence, major promises of personalized medicine have not yet materialized in improving patient or population outcomes. Several omics fields increasingly realize the need to safeguard the validity of their efforts, make reporting more transparent, and improve the translational potential of their studies. Many discoveries point indeed toward a highly individualized profile of health and disease, where each case is different, but this is currently difficult to translate into more effective personalized treatment or prevention. Given the exponential growth of collected data, understanding is often drowning in the sea of measurements.

Entities:  

Mesh:

Year:  2010        PMID: 20573481     DOI: 10.1016/j.jclinepi.2010.04.002

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  23 in total

Review 1.  Personalized medicine: understanding probabilities and managing expectations.

Authors:  Zachary Laksman; Allan S Detsky
Journal:  J Gen Intern Med       Date:  2010-09-28       Impact factor: 5.128

2.  Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.

Authors:  Ewout W Steyerberg; Michael J Pencina; Hester F Lingsma; Michael W Kattan; Andrew J Vickers; Ben Van Calster
Journal:  Eur J Clin Invest       Date:  2011-07-05       Impact factor: 4.686

3.  Lessons from Mackenzie that still resonate.

Authors:  Oliver van Hecke; Blair H Smith; Frank M Sullivan
Journal:  Br J Gen Pract       Date:  2013-03       Impact factor: 5.386

4.  One thing leads to another: the cascade of obligations when researchers report genetic research results to study participants.

Authors:  Fiona Alice Miller; Robin Zoe Hayeems; Li Li; Jessica Peace Bytautas
Journal:  Eur J Hum Genet       Date:  2012-02-15       Impact factor: 4.246

5.  Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?

Authors:  Jack E James
Journal:  Eur J Epidemiol       Date:  2014-04-12       Impact factor: 8.082

6.  Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis.

Authors:  Timo Itzel; Peter Scholz; Thorsten Maass; Markus Krupp; Jens U Marquardt; Susanne Strand; Diana Becker; Frank Staib; Harald Binder; Stephanie Roessler; Xin Wei Wang; Snorri Thorgeirsson; Martina Müller; Peter R Galle; Andreas Teufel
Journal:  Bioinformatics       Date:  2014-09-18       Impact factor: 6.937

Review 7.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

8.  Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes.

Authors:  Mirjam A G Sprangers; Jeff A Sloan; Andrea Barsevick; Cynthia Chauhan; Amylou C Dueck; Hein Raat; Quiling Shi; Cornelis J F Van Noorden
Journal:  Qual Life Res       Date:  2010-10-14       Impact factor: 4.147

Review 9.  Studying Cellular Signal Transduction with OMIC Technologies.

Authors:  Benjamin D Landry; David C Clarke; Michael J Lee
Journal:  J Mol Biol       Date:  2015-08-03       Impact factor: 5.469

10.  After the revolution? Ethical and social challenges in 'personalized genomic medicine'

Authors:  Eric T Juengst; Richard A Settersten; Jennifer R Fishman; Michelle L McGowan
Journal:  Per Med       Date:  2012-06-01       Impact factor: 2.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.